Skip to Main Content

Paper Details

Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus.
bioRxiv
0
2024
BQ.1, COVID-19, SARS, SARS-CoV, SARS-CoV-, SARS-CoV-2, infectious diseases, spike protein, wild-type SARS-CoV-2 spike protein
Author NameAffiliation
Natalia E KetarenThe Rockefeller University
Fred D MastCenter for Global Infectious Disease Research, Seattle Children's Research Institute
Peter C FridyThe Rockefeller University
Paul OlivierCenter for Global Infectious Disease Research, Seattle Children's Research Institute
Tanmoy SanyalDepartment of Pharmaceutical Chemistry, 17 California Institute for Quantitative Biosciences, University of California san francisco
Andrej Sali (CM4AI)Department of Pharmaceutical Chemistry, 17 California Institute for Quantitative Biosciences, University of California san francisco
Andrej Sali (CM4AI)Department of Pharmaceutical Chemistry, 17 California Institute for Quantitative Biosciences, University of California san francisco
Brian T ChaitThe Rockefeller University
Brian T ChaitThe Rockefeller University
Michael P RoutThe Rockefeller University
Michael P RoutThe Rockefeller University
John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute
John D AitchisonUniversity of Washington
John D AitchisonUniversity of Washington
  • 1 - 14

Datasets

Release 1.2